Dimethylpolysiloxane vs Recombinant Bovine Growth Hormone: which is worse?

What is Dimethylpolysiloxane?

Dimethylpolysiloxane (PDMS, polydimethylsiloxane) is a silicone-based polymer used as an antifoaming agent in food and beverages. It prevents the formation of foam during food manufacturing and cooking. It is the same base material used in silicone cookware, medical devices, and contact lenses.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Dimethylpolysiloxane: Dimethylpolysiloxane is generally considered non-toxic. It is not absorbed by the gut and passes through the digestive system unchanged. The FDA permits it at up to 10 ppm in cooking oils. EFSA's evaluation found no evidence of toxicity at permitted food use levels. There are no established cancer or reproductive toxicity concerns with PDMS at food use concentrations. The compound is the same base polymer used in many safe medical applications including contact lenses and breast implants (though the medical grade is different purity). The main environmental concern is PDMS persistence in the environment, as it is not readily biodegradable. Primary consumer concern is psychological rather than toxicological: the fact that it is used in both McDonald's frying oil and Silly Putty (which also contains PDMS) generates public attention, but the chemistries are actually different grades of the same polymer family.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.